AZN News and Press, AstraZeneca PLC From 06/12/24

US patients aged 10 years and older can now benefit from FARXIGA for type-2 diabetes Approval based on results from T2NOW, one of the largest pediatric type-2 diabetes Phase III trials to date AstraZeneca’s FARXIGA ® (dapagliflozin) has been approved by the...

2024-06-12 15:30:16 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca’s Tagrisso gets FDA pr...

2024-06-12 03:27:58 ET Summary Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities. Enhertu, the primary revenue driver today, has shown promising r...

2024-06-11 11:25:13 ET Summary The BlackRock Enhanced International Dividend Trust offers attractive geographical diversification and a high level of income with a yield of 7.28%. The BGY closed-end fund's lower yield compared to similar funds appears to be partly due to its less ...

(NewsDirect) Compared to their non-orphan counterparts, orphan drugs have consistently outpaced growth and have become a major part of pharma’s mainstream business. The U.S. FDA's orphan drug designation, established under the Orphan Drug Act of 1983, encourages the development of trea...

Decision based on LAURA Phase III trial results which extended median progression-free survival by more than three years TAGRISSO also granted Breakthrough Therapy Designation in US in this setting AstraZeneca’s supplemental New Drug Application (sNDA) for TAGRI...

2024-06-09 05:15:00 ET Summary Structure Therapeutics raises $476 million through an offering of its ADSs after announcing positive clinical results for its obesity drug. Suzhou Alphamab Oncology partners with ArriVent BioPharma to develop antibody drug conjugates, potentially rec...

2024-06-08 10:19:36 ET More on AstraZeneca, Bristol-Myers, etc. Merck & Co., Inc. (MRK) Investor Event at ASCO 2024 (Transcript) Bristol-Myers: Why I Am Buying More Of This Falling Knife, Yielding 5.84% Bristol-Myers Squibb: Looking Beyond The One-Time Quarterly ...

2024-06-07 12:30:37 ET Summary iShares Global Healthcare ETF has underperformed the S&P 500 index in the past few years. IXJ has lower volatility and downside risk compared to the broader market. The healthcare sector is expected to have strong earnings growth in 2024 and ...

2024-06-06 09:07:10 ET Summary AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC. Bristol...